MA31003B1 - Inhibiteurs de renine pour la prevention et le traitement de l'hypertension chez les patients obeses - Google Patents

Inhibiteurs de renine pour la prevention et le traitement de l'hypertension chez les patients obeses

Info

Publication number
MA31003B1
MA31003B1 MA32007A MA32007A MA31003B1 MA 31003 B1 MA31003 B1 MA 31003B1 MA 32007 A MA32007 A MA 32007A MA 32007 A MA32007 A MA 32007A MA 31003 B1 MA31003 B1 MA 31003B1
Authority
MA
Morocco
Prior art keywords
prevention
hypertension
obese patients
treatment
renin inhibitors
Prior art date
Application number
MA32007A
Other languages
English (en)
Inventor
Margaret Forney Prescott
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39186152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31003(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31003B1 publication Critical patent/MA31003B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES PROCÉDÉS DE PRÉVENTION, DE RETARD DE PROGRESSION OU DE TRAITEMENT DE L'HYPERTENSION CHEZ DES PATIENTS OBÈSES, COMPRENANT L'ADMINISTRATION À UN ANIMAL À SANG CHAUD D'UNE QUANTITÉ THÉRAPEUTIQUEMENT EFFICACE D'UN INHIBITEUR DE RÉNINE TEL QUE L'ALISKIRÈNE OU D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE. L'INHIBITEUR DE RÉNINE PEUT ÊTRE UTILISÉ SEUL OU EN COMBINAISON AVEC UN AUTRE ANTIHYPERTENSEUR, EN PARTICULIER UN DIURÉTIQUE TEL QUE L'HYDROCHLOROTHIAZIDE.
MA32007A 2006-12-15 2009-06-17 Inhibiteurs de renine pour la prevention et le traitement de l'hypertension chez les patients obeses MA31003B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87018006P 2006-12-15 2006-12-15

Publications (1)

Publication Number Publication Date
MA31003B1 true MA31003B1 (fr) 2009-12-01

Family

ID=39186152

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32007A MA31003B1 (fr) 2006-12-15 2009-06-17 Inhibiteurs de renine pour la prevention et le traitement de l'hypertension chez les patients obeses

Country Status (18)

Country Link
US (1) US20100029775A1 (fr)
EP (1) EP2094259A1 (fr)
JP (1) JP2010513300A (fr)
KR (1) KR20090090384A (fr)
CN (1) CN101583355A (fr)
AU (1) AU2007333095B2 (fr)
BR (1) BRPI0721167A2 (fr)
CA (1) CA2672579A1 (fr)
CL (1) CL2007003628A1 (fr)
IL (1) IL198876A0 (fr)
MA (1) MA31003B1 (fr)
MX (1) MX2009006340A (fr)
NO (1) NO20092597L (fr)
RU (1) RU2009126741A (fr)
TN (1) TN2009000240A1 (fr)
TW (1) TW200831071A (fr)
WO (1) WO2008074001A1 (fr)
ZA (1) ZA200903442B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2143425A1 (fr) * 2008-07-11 2010-01-13 Ratiopharm GmbH Tablettes d'aliskiren comprimées directement

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
TW200538154A (en) * 2004-02-17 2005-12-01 Novartis Ag Combination of organic compounds
BRPI0508880A (pt) * 2004-03-17 2007-09-04 Novartis Ag uso de compostos orgánicos
WO2007047351A2 (fr) * 2005-10-13 2007-04-26 Orexigen Therapeutics, Inc. Méthodes pour traiter l'hypertension chez des individus en surpoids et obèses
WO2007146900A2 (fr) * 2006-06-15 2007-12-21 Gilead Colorado, Inc. Procédé de traitement antihypertenseur

Also Published As

Publication number Publication date
US20100029775A1 (en) 2010-02-04
CA2672579A1 (fr) 2008-06-19
RU2009126741A (ru) 2011-01-20
KR20090090384A (ko) 2009-08-25
WO2008074001A8 (fr) 2009-07-02
NO20092597L (no) 2009-07-13
EP2094259A1 (fr) 2009-09-02
WO2008074001A1 (fr) 2008-06-19
TW200831071A (en) 2008-08-01
CL2007003628A1 (es) 2008-07-18
AU2007333095B2 (en) 2011-03-24
JP2010513300A (ja) 2010-04-30
IL198876A0 (en) 2010-02-17
MX2009006340A (es) 2009-06-23
CN101583355A (zh) 2009-11-18
ZA200903442B (en) 2010-05-26
BRPI0721167A2 (pt) 2014-03-18
AU2007333095A1 (en) 2008-06-19
TN2009000240A1 (en) 2010-10-18

Similar Documents

Publication Publication Date Title
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
MA32132B1 (fr) Utilisation de ranolazine pour traiter la douleur
MA31205B1 (fr) Combinaisons d'agents therapeutiques pour le traitement du cancer
MA31663B1 (fr) Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe
MA31396B1 (fr) Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes
MA32049B1 (fr) Traitement du cancer avec des combinaisons d'inhibiteurs de topoisomerase et d'inhibiteurs de parp
MA32397B1 (fr) Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité
MA30128B1 (fr) Combinaisons pharmaceutiques d'un antagoniste de receptuer d'angiotensine et d'un inhibiteur de nep
MA31707B1 (fr) Dérivés de benzimidazole et d'indole substitués par de l'oxadiazole et oxazole comme inhibiteurs de dgat1
NZ597648A (en) Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
EP2063882A4 (fr) Inhibiteurs de kinase pour la prévention ou le traitement d'une infection
MA29915B1 (fr) Benzimidazoles substitues utilises en tant qu'inhibiteurs de kinases
MA33056B1 (fr) Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon
EP1606264A4 (fr) Antagonistes des recepteurs du cgrp d'anilide spirohydantoine monocyclique
GEP20125691B (en) Compounds and compositions as protein kinase inhibitors
UA97795C2 (uk) Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
EA200100937A1 (ru) Способы и композиции, использующие (-)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов
EP2192920A4 (fr) Procédés et compositions pour le traitement ou la prévention d'une fibrose induite par rayonnement
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
NO20085051L (no) Behandling av gastrointestinale forstyrrelser med CGRP-antagonister
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
MA31003B1 (fr) Inhibiteurs de renine pour la prevention et le traitement de l'hypertension chez les patients obeses
TW200744584A (en) Use of mGluR5 antagonists (ESP. AFQ056) in GI (ESP. GERD)
WO2008030595A3 (fr) Traitement, prévention et élimination d'une hépatopathie alcoolique